Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy

John S. Runge, PhD, Anna B. Brown, PharmD, BCOP, Tycel J. Phillips, MD, Mark S Kaminski, MD, Shannon A. Carty, MD, Ryan A. Wilcox, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134151

Published: 2020

Journal Articles

Risk of Opportunistic Infections in Patients with Bendamustine-Associated Lymphopenia and the Utility of Antimicrobial Prophylaxis

Jayasree Krishnan, MD, Victoria Nachar, PharmD, Bernard Lawrence Marini, PharmD, Anthony J. Perissinotti, PharmD, Tycel J. Phillips, MD, Mark S Kaminski, MD, Shannon A. Carty, MD, Ryan A. Wilcox, MD

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-142763

Published: 2020

Journal Articles

Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016

Richard Burack, MD PhD, Hongli Li, MS, Diana G Adlowitz, PhD, Janice M Spence, PhD, Michael L. Leblanc, PhD, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Catherine M. Spier, MD, Mark S Kaminski, MD, John P. Leonard, MD, Richard I. Fisher, MD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 2771.

https://doi.org/10.1182/blood-2019-121632

Published: 2019

Journal Articles

Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial

Blood (2018) 132 (Supplement 1): 2921.

https://doi.org/10.1182/blood-2018-99-111893

Published: 2018

Journal Articles

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Richard Burack, MD PhD, Hongli Li, MS, Janice M Spence, PhD, Diana Adlowitz, Lisa M. Rimsza, MD, Rita M. Braziel, MD, Catherine M. Spier, MD, Mark S Kaminski, MD, John P. Leonard, MD, Richard I. Fisher, MD, Michael L. Leblanc, PhD, Sonali M. Smith, MD, Jonathan W. Friedberg, MD

Blood (2018) 132 (Supplement 1): 919.

https://doi.org/10.1182/blood-2018-99-111399

Published: 2018

Journal Articles

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Fares Alsawah, MD BS, MS, Samuel A. Merrill, MD PhD, Paula L. Bockenstedt, MD, Erica L. Campagnaro, MD, Sumana Devata, MD, Scott D. Gitlin, MD, Mark S Kaminski, MD, Alice M. Cusick, MD, Tycel J. Phillips, MD, Suman L. Sood, MD, Moshe Talpaz, MD, Albert Thomas Quiery, MD, Philip S Boonstra, PhD, Asra Z. Ahmed, MD, Ryan A. Wilcox, MD PhD

Blood (2018) 132 (Supplement 1): 1119.

https://doi.org/10.1182/blood-2018-99-116854

Published: 2018

Journal Articles

Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States

Blood (2017) 130 (Supplement 1): 377.

https://doi.org/10.1182/blood.V130.Suppl_1.377.377

Published: 2017

Journal Articles

Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)

Janie Y Zhang, MD, Robert Briski, BS, Sumana Devata, MD, Mark S Kaminski, MD, Tycel Phillips, MD, Tera Mayer, NP, Nathanael G Bailey, MD, Ryan A Wilcox, MD PhD

Blood (2016) 128 (22): 4152.

https://doi.org/10.1182/blood.V128.22.4152.4152

Published: 2016

Journal Articles

Functional Analyses of V-Atpase Mutations in Follicular Lymphoma

Fangyang Wang, Damian Gatica, Zhang Xiao Ying, Luke F. Peterson, Denzil Bernard, Kamlai Saiya-Cork, Shaomeng Wang, Alfred Chang, Mark S Kaminski, MD, Tycel Phillips, MD, Daniel Klionsky, Sami N. Malek

Blood (2016) 128 (22): 1762.

https://doi.org/10.1182/blood.V128.22.1762.1762

Published: 2016

Journal Articles

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Mazyar Shadman, MD MPH, Hongli Li, PhD, Lisa Rimsza, MD, John P. Leonard, MD, Mark S Kaminski, MD, Rita M Braziel, MD, Catherine M. Spier, MD, Ajay K Gopal, MD, David G Maloney, MD PhD, Bruce Cheson, MD, Shaker Dakhil, MD FACP, Michael LeBlanc, PhD, Sonali M. Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD, Oliver Press, MD PhD

Blood (2016) 128 (22): 616.

https://doi.org/10.1182/blood.V128.22.616.616

Published: 2016

Journal Articles

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Kent A. Griffith, MPH, MS, Kathryn McDonnell, BS, Daniel Lebovic, MD, Malathi Kandarpa, PhD, David H. Vesole, MD, PhD, Sundar Jagannath, MD, Melissa A. Mietzel, MS CCRP, Ravi Vij, MD, Malek Faham, MD, PhD, Liana Lee, BS, Erik H. van Beers, PhD, Martin H. van Vliet, PhD, Joan Levy, PhD, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark S. Kaminski, MD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 3220.

https://doi.org/10.1182/blood.V122.21.3220.3220

Published: 2013

Journal Articles

Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g)

Andrew D Zelenetz, MD, PhD, Mehrdad Mobasher, MD, MPH, Luciano J Costa, MD, PhD, Ian Flinn, MD, PhD, Christopher R. Flowers, MD, MS, Mark S. Kaminski, MD, Thomas Sandmann, PhD, Kerstin Trunzer, PhD, Charlotte Vignal, MSc, PhD, Andres Forero-Torres, MD

Blood (2013) 122 (21): 1820.

https://doi.org/10.1182/blood.V122.21.1820.1820

Published: 2013

Journal Articles

Recurrent STAT6 Mutations In Follicular Lymphoma

Sami Malek, MD, Mark S. Kaminski, MD, Hongxiu Li, PhD, Peter Ouillette, Sian Jones, PhD, Heather Fox, PA-C, Kathryn Jacobi, NP, Kamlai Saiya-Cork, Dale Bixby, MD, PhD, Daniel Lebovic, MD, Kerby Shedden, PhD, Michael Sabel, MD, Lawrence Marentette, MD, Vincent Cimmino, MD, Alfred Chang, MD, Mehmet Yildiz, MD

Blood (2013) 122 (21): 503.

https://doi.org/10.1182/blood.V122.21.503.503

Published: 2013

Journal Articles

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

Alex F Herrera, MD, Allison Crosby-Thompson, Jonathan W. Friedberg, MD, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Joyce Niland, PhD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Ann S. LaCasce, MD

Blood (2012) 120 (21): 1610.

https://doi.org/10.1182/blood.V120.21.1610.1610

Published: 2012

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Rebecca L. Elstrom, MD, John P. Leonard, MD, Paul Christos, Peter Martin, MD, Daniel Lebovic, MD, Joseph Osborne, Stanley J. Goldsmith, June Greenberg, RN, Richard R. Furman, MD, Jia Ruan, MD, PhD, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 1636.

https://doi.org/10.1182/blood.V120.21.1636.1636

Published: 2012

Journal Articles

A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM)

Daniel Lebovic, MD, Mark S. Kaminski, MD, Tara B. Anderson, Kristen Detweiler-Short, Kent A. Griffith, Terri L. Jobkar, BSN, Malathi Kandarpa, PhD, Andrzej Jakubowiak, MD, PhD

Blood (2012) 120 (21): 1854.

https://doi.org/10.1182/blood.V120.21.1854.1854

Published: 2012

Journal Articles

Analysis of the Coding Genome of Follicular Lymphoma Identifies Multiple Novel Recurrently Mutated Genes

Sami Malek, MD, Yifeng Li, MD, Hongxiu Li, PhD, Peter Ouillette, Sian Jones, PhD, Heather Fox, Kathryn Jacobi, Kamlai saiya-Cork, Dale Bixby, MD PhD, Daniel Lebovic, MD, Kerby Shedden, PhD, Michael Sabel, MD, Lawrence Marentette, MD, Vincent Cimmino, MD, Alfred Chang, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 147.

https://doi.org/10.1182/blood.V120.21.147.147

Published: 2012

Journal Articles

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Zheng Zhou, MD, PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Ann Vanderplas, MS, Allison Crosby-Thompson, Andrew D Zelenetz, MD, PhD, Gregory A. Abel, MD, MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark S. Kaminski, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Joyce Niland, PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2012) 120 (21): 2656.

https://doi.org/10.1182/blood.V120.21.2656.2656

Published: 2012

Journal Articles

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Makiko Ban-Hoefen, MD, Ann Vanderplas, MS, Jennifer L. Kelly, PhD, MPH, Allison Crosby-Thompson, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Joyce Niland, PhD, Ann LaCasce, MD, Jonathan W. Friedberg, MD

Blood (2012) 120 (21): 2669.

https://doi.org/10.1182/blood.V120.21.2669.2669

Published: 2012

Journal Articles

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

Oliver W. Press, MD, PhD, Joseph M Unger, Ph.D., Lisa M. Rimsza, MD, Jonathan Friedberg, MD, Michael LeBlanc, Ph.D., Myron S. Czuczman, MD, Mark S. Kaminski, MD, Rita M. Braziel, MD, David G. Maloney, MD, PhD, Bruce D. Cheson, MD, Thomas P. Miller, MD, Richard I Fisher, MD

Blood (2011) 118 (21): 98.

https://doi.org/10.1182/blood.V118.21.98.98

Published: 2011

NARROW

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy

Risk of Opportunistic Infections in Patients with Bendamustine-Associated Lymphopenia and the Utility of Antimicrobial Prophylaxis

Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016

Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial

Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Multicenter Retrospective Study of Features and Outcomes of Patients with Intravascular DLBCL Treated at Academic Institutions within the United States

Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)

Functional Analyses of V-Atpase Mutations in Follicular Lymphoma

Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g)

Recurrent STAT6 Mutations In Follicular Lymphoma

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM)

Analysis of the Coding Genome of Follicular Lymphoma Identifies Multiple Novel Recurrently Mutated Genes

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only